共被期刊论文引用了4次
您的检索式：您选中1篇文献正在查看引证文献汇总
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Irritable bowel syndrome:A clinical review显示文摘Irritable bowel syndrome(IBS)remains a clinical challenge in the 21st century.It’s the most commonly diagnosed gastrointestinal condition and also the most common reason for referral to gastroenterology clinics.Its can affect up to one in five people at some point in their lives,and has a significantly impact of life quality and health care utilization.The prevalence varies according to country and criteria used to define IBS.Various mechanisms and theories have been proposed about its etiology,but the biopsychosocial model is the most currently accepted for IBS.The complex of symptoms would be the result of the interaction between psychological,behavioral,psychosocial and environmental factors.The diagnosis of IBS is not confirmed by a specific test or structural abnormality.It is made using criteria based on clinical symptoms such as Rome criteria,unless the symptoms are thought to be atypical.Today the Rome CriteriaⅢis the current goldstandard for the diagnoses of IBS.Secure positive evidence of IBS by means of specific disease marker is currently not possible and cannot be currently recommended for routine diagnosis.There is still no clinical evidence to recommend the use of biomarkers in blood to diagnose IBS.However,a number of different changes in IBS patients were demonstrated in recent years,some of which can be used in the future as a diagnostic support.IBS has no definitive treatment but could be controlled by non-pharmacologic management eliminating of some exacerbating factors such certain drugs,stressor conditions and changes in dietary habits.The traditional pharmacologic management of IBS has been symptom based and several drugs have been used.However,the cornerstone of its therapy is a solid patient physician relationship.This review will provide a summary of pathophysiology,diagnostic criteria and current and emerging therapies for IBS. | Rosa LS Soares | 2014 | World Journal of Gastroenterology2014，20，34： | 16 |
| 2 | 2022中国功能性消化不良诊治专家共识显示文摘功能性消化不良(FD)是消化系统常见疾病,全球人口患病率>10%。2016年罗马Ⅳ标准对FD的定义、诊断标准和分型进行了更新,近几年我国FD的基础、临床研究也取得很大进展。为及时更新对FD的认识,规范临床诊疗,中华医学会消化病学分会组织相关领域专家,在2015年我国FD诊治共识意见的基础上,根据国际最新进展和我国研究证据,制定了2022中国FD诊治专家共识。本专家共识涉及FD的定义、发病机制、诊断和评估、药物和非药物治疗,以及难治性FD等方面内容。 | 中华医学会消化病学分会胃肠动力学组 中华医学会消化病学分会胃肠功能性疾病协作组 陈旻湖 方秀才 侯晓华 李延青 唐旭东 肖英莲 邹多武 | 2023 | 中华消化杂志2023，43，7： | 4 |
| 3 | 感染后肠功能紊乱和树突状细胞的关系显示文摘目前感染后肠功能紊乱的免疫学发病机制仍不清楚,免疫细胞的激活可能会导致肠道动力和感觉功能的改变,其中重要的抗原提呈细胞如树突状细胞(dendritic cells,DC)在免疫细胞的激活中发挥着重要的作用。肠道组织中的树突状细胞可以激活初始和适应性免疫应答,产生Th1和Th2型细胞因子,这些细胞因子可以引起肠道神经肌肉功能的改变,从而使肠道功能发生紊乱。 | 周政 王巧民 | 2009 | 胃肠病学和肝病学杂志2009，18，10： | 2 |
| 4 | 感染后肠易激综合征显示文摘 | 陈翔 侯晓华 | 2010 | 临床荟萃2010，25，8： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员